Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies

Author(s):

Guillermo Garcia-Manero, MDRami Komrokji, MD

The experts describe their strategies for selecting first-line treatments in lower-risk myelodysplastic syndrome patients, focusing on the key factors that inform their sequencing decisions in frontline therapy.

EP: 1.Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification

EP: 2.Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 

Now Viewing

EP: 3.Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies

EP: 4.Review of the COMMANDS Trial

EP: 5.Practing Changing? Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial

EP: 6.Clinical Implications of COMMANDS Trial in Clinical Practice

Dr Garcia-Manero to panelist: Please outline your current approach to 1L treatment selection for patients with lower-risk MDS.
1. What factors guide your frontline selection of therapy?
2. How does your approach compare between U.S. and non-U.S. physicians?